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This joint position paper illustrates the role and the correct use of echocardiography, radionuclide imaging with
18F-fluorodeoxyglucose positron emission tomography, radionuclide myocardial perfusion imaging and cardiovascu-
lar magnetic resonance imaging for the evaluation and management of patients with known or suspected cardiac
sarcoidosis. This position paper will aid in standardizing imaging for cardiac sarcoidosis and may facilitate clinical tri-
als and pooling of multi-centre data on cardiac sarcoidosis. Proposed flow charts for the work up and management
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This procedural position paper on the use of imaging in the manage-
ment of patients with known or suspected cardiac sarcoidosis has
been developed under the auspices of the Cardiovascular and the
Inflammation & Infection Committee of the European Association of
Nuclear Medicine (EANM), the European Association of
Cardiovascular Imaging (EACVI) of the European Society of
Cardiology (ESC), and the American Society of Nuclear Cardiology
(ASNC), highlighting the close collaboration between the societies
on this topic.
Introduction
Sarcoidosis is a multisystem inflammatory granulomatous disease of
unknown origin. Granulomas in sarcoidosis are compact, centrally
organized collections of macrophages and epithelioid cells that are
surrounded by lymphocytes. Granulomas from sarcoidosis are most
often located in the lungs or its associated lymph nodes, but any
organ can be affected.
Sarcoidosis affects approximately 10 out of 100 000 persons each
year.1 Cardiac sarcoidosis is reported to involve only 2–5% of
patients with systemic sarcoidosis,2,3 even though autopsy studies
indicate a considerably greater prevalence of 27%.4,5 There is also
evidence indicating that sarcoidosis can be clinically confined to the
heart.6 Cardiac involvement may range from silent myocardial granulo-
mas to symptomatic conduction disturbances, ventricular arrhyth-
mias, progressive heart failure, and sudden death, accounting for 13–
25% of disease-related deaths.5 The clinical course of cardiac sarcoi-
dosis varies from benign to life-threatening with severe heart failure
and sudden cardiac death.7 The management of cardiac sarcoidosis
involves both immunosuppressive therapy for the treatment of sar-
coidosis and cardiac-specific therapies to manage ventricular
































































































dysfunction and device therapy (pacemaker/ICD) for heart blocks
and heart rhythm disturbances. The decision for drug therapy alone
or the implantation of an ICD for primary prevention in the early
stage of cardiac sarcoidosis remains challenging. Nevertheless, it is
felt that early initiation of immunosuppressive therapy may prevent
progression of cardiac dysfunction and improve clinical outcomes.8
To date, the diagnosis and long-term management of cardiac
involvement remain controversial. Cardiac sarcoid granulomas affect
the whole heart but in a focal manner. Also, acutely inflamed epithe-
loid cell granulomas as well as chronic fibrotic stage granulomas, may
exist in different parts of the heart of any given patient.
Consequently, blind endomyocardial biopsy of the right side of the
interventricular septum has a low diagnostic yield, 20–30%, and it is
unreliable to assess whole heart burden of inflammation or fibrosis.
Molecular imaging of increased metabolic activity in the granulomas
using 18F-fluorodeoxyglucose (FDG) positron emission tomography
(PET) provides the advantages of whole heart evaluation and the abil-
ity to identify granulomas with active inflammation. Cardiovascular
magnetic resonance (CMR) on the other hand is highly sensitive to
detect fibrosis. The Japanese Ministry of Health, Labour and Welfare
(JMHW) criteria have been widely used for the diagnosis of cardiac
sarcoidosis. But, they do not include FDG-PET or CMR.9 The Heart
Rhythm Society (HRS) consensus document has included FDG-PET
and CMR in the diagnostic criteria for cardiac sarcoidosis.10
However, procedural details of imaging are not covered in that
document.
The purpose of this joint procedural position paper is to describe
the role and the correct use of the different imaging techniques
including radionuclide imaging (FDG-PET, radionuclide myocardial
perfusion imaging, MPI), CMR, and echocardiography for the manage-
ment of patients with known or suspected cardiac sarcoidosis. We
further hope that this position paper will aid in standardizing imaging
for cardiac sarcoidosis with conventional and novel imaging techni-
ques and facilitate clinical studies and pooling of multi-center data on
cardiac sarcoidosis.
Role of different imaging
techniques in cardiac sarcoidosis
Echocardiography
Rationale
Echocardiography is widely available and often provides the first sus-
picion for cardiac sarcoidosis.
Image acquisition
Several traditional and advanced echocardiographic approaches can
be used with standard acquisition and interpretation protocols.11–18
Stress echocardiography has a limited role in the diagnosis of cardiac
sarcoidosis; it may be helpful to exclude epicardial coronary artery
disease as a cause of left ventricular systolic dysfunction and focal
regional wall motion abnormalities.
Interpretation and reporting
Cardiac sarcoidosis can manifest with normal function or with
dilated or restrictive cardiomyopathy.19–21 The ventricle may be
globally hypokinetic or the patchy nature of sarcoid infiltration of
the heart may result in regional wall motion abnormalities in a
non-coronary distribution. Mild wall thickening may be present
related to oedema or infiltration. In some cases, the increase in
myocardial wall thickness (>13 mm) can simulate LV hypertrophy.
Increased ventricular wall echogenicity (bright aspect), particu-
larly the ventricular septum or the LV free wall, is frequent; and
can reflect scar formation and granulomatous inflammation. More
commonly, areas of wall thinning are seen, especially in the ven-
tricular septum, probably as a result of scar. A typical but uncom-
mon finding is the thinning (<7 mm) and akinesia of the basal
septum, while the distal septum and apex are contracting nor-
mally, and the presence of ventricular aneurysm in the inferolat-
eral wall20,22–24 (Figure 1). Echocardiographic features of cardiac
sarcoidosis echo can also mimic arrhythmogenic right ventricular
dysplasia/cardiomyopathy.25,26 In the early stage of the disease,
reduced longitudinal myocardial function (2D speckle tracking or
tissue Doppler imaging-derived strain)27–32 or alterations in
acoustic properties of the myocardium,33,34 particularly in the
basal interventricular septum, may be present in the absence of
other 2D echo features. About 20% of patients with cardiac sar-
coidosis have atrial lesions characterized by atrial wall hypertro-
phy (easier diagnosis by transoesophageal echocardiography).35
On rare occasions, an appearance similar to hypertrophic cardio-
myopathy can be observed.36,37 Any degree of diastolic dysfunc-
tion is a common but non-specific finding.38 Small pericardial
effusions, mitral or tricuspid regurgitation secondary to papillary
muscle dysfunction, pulmonary hypertension secondary to lung
implication, and/or ventricular dys-synchrony are other echo
parameters that can be potentially observed in cardiac sarcoidosis.
Tamponade and constrictive pericarditis have been infrequently
found.19 The right ventricular dilatation and dysfunction at the
end-stage disease in cardiac sarcoidosis as well as the predomi-
nance of basal septum abnormalities in terms of contractility are
important findings on echocardiography.25
Diagnostic accuracy
Echocardiography can detect cardiac structural abnormalities from
cardiac sarcoidosis. But in patients with extra-cardiac sarcoidosis,
echocardiographic abnormalities are highly variable, ranging from 4
to 55%, even without clinical symptoms or ECG abnormalities.3,10
The measurement of LV systolic and diastolic function and evaluation
of valvular disease severity are not-specific for sarcoidosis.39
Although newer techniques such as Doppler, strain, and speckle
tracking echocardiography are useful in detecting abnormal myocar-
dial function, these imaging techniques cannot delineate tissue char-
acteristics and therefore cannot differentiate between various types
of cardiomyopathies.40 Using the criteria of RV systolic dysfunction in
the absence of pulmonary hypertension, and/or significant diastolic
dysfunction inappropriate for the patient’s age, echocardiography
yields a sensitivity of 10–47% and a specificity of 82–99% for the diag-
nosis of cardiac sarcoidosis.10,41
In summary, standard 2D transthoracic echocardiography is a
common initial test in patients with suspected cardiac sarcoidosis.
However, findings are frequently non-specific for inflammation and
not sensitive for early changes from sarcoidosis. The primary role of
































echocardiography in cardiac sarcoidosis, at this time, is to assess and
follow LV function.
Radionuclide imaging
Radionuclide imaging with 67Gallium-citrate SPECT and FDG-PET
have been used to diagnose myocardial inflammation. 67Gallium-cit-
rate is specific for inflammation, but has relatively low sensitivity and
poor spatial resolution compared with FDG-PET, especially for
detecting extra-pulmonary sarcoidosis involvement.42 Therefore, the
use of 67Gallium-citrate SPECT to diagnose cardiac sarcoidosis is lim-
ited to centres without access to FDG PET. FDG-PET has emerged
as a powerful and most commonly used technique not only to assess
the extent of systemic sarcoidosis but also to assess extent and
activity of myocardial involvement.43 In addition, recent studies have
demonstrated the importance of identifying perfusion defects in
patients with cardiac sarcoidosis, as this group of patients is at highest
risk for death or ventricular arrhythmias.44,45 FDG-PET in conjunc-
tion with MPI is therefore the currently recommended radionuclide




Active inflammatory cells have high glycolytic activity to sustain their
energy demands; the accumulation of FDG in these activated macro-
phages and CD4þT lymphocytes is the underlying mechanism for
in vivo visualization of active granulomatous sarcoid lesions in various
Figure 1 Example of echocardiography in cardiac sarcoidosis. Echocardiographic images showing (A) a basal thinned basal septal wall (4-chamber
view showing, arrows); (B–D) aneurysmal dilatation involving inferior (B, D) and posterolateral (C) walls. D is a 3D image displaying the inferior aneur-
ysm (arrows).































































..organs.46 Low carbohydrate diet and prolonged fasting of the subject
are recommend to suppress myocardial FDG uptake to facilitate vis-
ualizing FDG uptake in these inflammatory cells of cardiac sarcoido-
sis. The role of FDG-PET for the diagnosis of extra-cardiac
sarcoidosis is well established; in contrast, its role in cardiac sarcoido-
sis management, and therapy is currently under active investigation.
Patient preparation and image acquisition
Metabolic imaging to identify the non-caseating granulomas of cardiac
sarcoidosis takes advantage of enhanced FDG uptake based on the
high glycolytic activity of inflammatory cells.47,48 However, the sur-
rounding normal myocardium can also use glucose as an energy sub-
strate, and therefore it is important to minimize physiological
myocardial glucose utilization to optimize the target to background
ratio of FDG-PET for identifying active cardiac sarcoid lesions. Patient
preparation for cardiac FDG-PET imaging for sarcoidosis is based on
increasing the provision of fatty acids to the heart and decreasing phys-
iological uptake of glucose by the myocardium.103 The current
SNMMI/ASNC/SCCT guidelines recommend preparation with a fat-
enriched diet lacking carbohydrates for 12–24 h prior to the scan, a
12–18 h fast, and/or the use of intravenous unfractionated heparin
approximately 15 min prior to 18F-FDG injection.49 Careful patient
preparation is critical to optimize FDG-PET image quality. Details of
patient preparation are listed in Supplementary data online, Supplement
1a and 1b.
The FDG-PET imaging protocol involves cardiac image
acquisition 90 min (minimum of 60 min) after intravenous injection of
2.5–5 MBq/kg of FDG.50–52 (Table 2). Following FDG injection and
before the images are obtained, the patient should continue to fast and
should not be physically active, as either of these will enhance myocar-
dial glucose uptake. In addition, limited whole body FDG imaging is rec-
ommended to allow for the assessment of extra-cardiac disease activity
(lung, lymph nodes, liver, spleen, kidneys, bones) and identify potential
sites amenable for biopsy. Imaging procedures, including dietary prepa-
ration and image acquisition parameters should be documented and
standardized on repeat studies, to enable reliable quantitation and
comparison of changes. Exercise and/or myocardial ischemia can
enhance myocardial FDG uptake. For this reason, stress testing should
be avoided and patients should be advised not to exert themselves on
the day of cardiac sarcoid FDG imaging. Also, note that patients with
systolic LV dysfunction may have increased glucose uptake due to meta-
bolic changes, which is likely diffuse rather than focal.
Interpretation and reporting
Interpretation of FDG-PET for cardiac sarcoidosis requires an under-
standing of the metabolic preparations necessary to differentiate the
pathological glucose uptake that is the hallmark of sarcoidosis-related
inflammation from physiological myocardial glucose uptake. It is also
important to note that none of the interpretive strategies described
below have been validated experimentally, due to the lack of a gold
standard, and there is little data available on comparing the various
methods. The most common method of interpreting FDG-PET for
the evaluation of cardiac sarcoidosis relies on the use of traditional
nuclear cardiology display systems as well as nuclear medicine display
systems.53 Typically short-axis, horizontal, and vertical long-axis
images of the FDG and rest MPI are displayed together with the
image intensity normalized to the maximum counts per pixel of the
respective data set. These normalized images are reviewed for four
imaging patterns54:
(1) No FDG uptake (‘none’)
(2) Diffuse FDG uptake (‘diffuse’)
(3) Focal FDG uptake (‘focal’)
(4) Focal on diffuse FDG uptake (‘focal on diffuse’).
The presence of ‘focal’ or ‘focal on diffuse’ FDG uptake is abnormal
and may be consistent with cardiac inflammation from sarcoidosis,
while interpretation of diffuse uptake is challenging as it can be non-
specific (possibly related to poor suppression of normal myocardial
glucose uptake) or may represent multiple sarcoid granulomas with
heterogeneous FDG uptake in a diffuse distribution. The normal
FDG image pattern for an appropriately prepared patient is no myo-
cardial FDG uptake where the LV blood pool is brighter than the
....................................................................................................................................................................................................................
Table 1 Sensitivity and specificity of FDG PET for detecting cardiac sarcoidosis
References Year Patients EMB* Sensitivity Specificity Remarks
Yamagishi et al.53 2003 17 0/17 100 n.a. Only patients with histologic evidence of extra-cardiac
sarcoidosis were included
Okumura et al.55 2004 22 3/22 100 90.9 Diagnosis JMHW
Ishimaru et al.54 2005 62 0/62 100 81.5 Included 30 healthy controls and 32 patients with
suspected sarcoidosis. Diagnosis 28 out of 32 with
histologic evidence of extra-cardiac sarcoidosis.
Nishiyama et al.42 2006 18 0/18 100 100 Diagnosis JMHW
Ohira et al.69 2008 21 2/21 87.5 38.5 Diagnosis JMHW
Langah et al.57 2009 65 1/65 85 90 Diagnosis JMHW
Youssef et al.70 2012 164 n.a. 89 78 Meta-analysis of 7 studies
Diagnosis JMHW

































..myocardium, although low intensity FDG uptake in the lateral wall is
also often considered a normal finding, particularly when such uptake
is homogenous in intensity and is not associated with any resting per-
fusion defects.54 In addition to evaluating for abnormal FDG uptake
in the LV, it is also important to evaluate for areas of focal FDG
uptake in the right ventricle, which may be associated with a worse
prognosis.45 Lastly, the use of FDG-PET combined with MPI will be
particularly helpful to judge the orientation of the image when only
focal FDG uptake is present.
The use of traditional nuclear cardiology display systems to inter-
pret relative FDG-PET images for cardiac sarcoidosis has two limita-
tions. First, since these display schemes normalize image intensity to
the most intense pixel, it is difficult to judge the absolute intensity of
myocardial FDG uptake. This may be important for understanding
the severity of myocardial inflammation and for evaluating the
response to treatment, particularly if only the intensity but not
the distribution of FDG uptake changes between studies. Secondly,
the issue of normalization is especially important when the FDG sig-
nal is only mildly increased above background. This can falsely cause
these areas of low absolute uptake to appear artificially intense in the
normalized display.
A review of the images for non-inflammatory pathological FDG
activity (cancer, other infections, etc.) is accomplished using limited
whole body hybrid PET/CT. Hybrid FDG-PET/CT imaging, however,
may be problematic in individuals with intra-cardiac devices due to
apparent focal increase in FDG uptake at the site of lead insertion
related to errors from CT based attenuation correction and/or focal
inflammation. In individuals with intra-cardiac devices and suspected
....................................................................................................................................................................................................................
Table 2 Procedure guidelines for radionuclide myocardial perfusion and FDG imaging for cardiac sarcoidosis
Imaging sequence Myocardial perfusion imaging and FDG PETat baseline Standard
Myocardial perfusion imaging and FDG PETat follow-up
Myocardial perfusion imaging
Preparation None Standard
Preparation for FDG PET, if performed on the same day
Technique PET or SPECT Standard
Perfusion radiotracers 99mTc-sestamibi/tetrofosmin, 201Tl, 13N-ammonia, 82Rb Standard
Protocols Standard radiotracer dose and rest MPI protocols as per ASNC, EANM, ESC Standard
Attenuation correction when available Standard
Gated SPECT/PET MPI Standard
Review Review MPI along with FDG PET
FDG PET imaging
Preparation Dietary preparation to minimize physiological myocardial glucose utilization Standard
Type of PET scan Hybrid PET/CT Standard
Dedicated PET Acceptable
CT scan Low dose chest CT scan for attenuation correction without iodinated contrast Standard
Imaging mode 3D Standard
2D Acceptable
Dose 2.5–5 MBq/kg for 3 D mode or Acceptable
5–10 mCi for 3 D imaging and 10-20 mCi for 2 D imaging Acceptable
FDG uptake period after injection 90 min Standard
60 min Minimum
Scan field of view Dedicated cardiac scan and whole body to include neck through pelvis at baseline Standard
Dedicated cardiac scan and whole body to include neck through pelvis at follow up Standard
Scan duration 10 min for 3D cardiac PET Standard
20 min for 2D cardiac PET Standard
3 min per bed position partial whole body PET Standard
Scan type Static FDG PET Standard
Gated FDG PET Optional
Scan reconstruction Iterative reconstruction (OSEM) Standard
Attenuation correction Standard
With and without attenuation correction for hybrid PET/CT in individuals with intracardiac devices Standard
Scan interpretation Visual using cardiac imaging planes Standard
Whole body imaging using SUV scale Standard
Myocardial SUV max Standard
Volume of myocardium above specific SUV threshold Standard
Interpretation by physicians experienced in nuclear cardiology, CT and FDG imaging Standard
Special considerations In individuals with recent intracardiac device placement or ablation wait 4–6 weeks for FDG PET Optional
































































































cardiac sarcoidosis, the non-attenuation corrected FDG images could
be reviewed to overcome this limitation.
In addition to a visual review of the relative scaled FDG images and
hybrid PET-CT images, FDG images should be assessed using a semi-
quantitative scale and standardized uptake values (SUV). SUVs are
defined as the (radioactivity concentration in the region of interest in
Bq/mL/(injected dose in Bq/patient weight in g).55 Various metrics for
quantification of FDG uptake in cardiac sarcoidosis have been
reported, including the maximal SUV values in the heart
(SUVmax),45,55 the total SUV value of the heart,55 mean SUV of the
heart,56 heart-to-blood pool SUV ratios,57 coefficient of variance of
SUVs,58 and the volume,59 and volume-activity44,59 of voxels with
intensities of FDG SUVs above various thresholds. While these
methods have not been rigorously compared head-to-head, there is
data to suggest that they perform better than visual assessment of
normalized images to assess treatment response.44,59,60 A standard
FDG-PET for cardiac sarcoidosis is typically reported in conjunction
with rest MPI (see Supplementary data online, Supplement 2).
Myocardial perfusion imaging
Cardiac sarcoidosis may alter coronary microcirculation leading to
myocardial perfusion defects. Myocardial perfusion abnormalities,
including reversible perfusion defects with adenosine or dipyrida-
mole, have been reported in cardiac sarcoidosis.56,61,62 However,
unlike with coronary artery disease, perfusion abnormalities related
to sarcoid granulomas typically do not match with coronary territo-
ries. In the chronic phase, when epithelioid-cell granulomas have
been replaced by fibrosis, perfusion defects become irreversible and
may be associated with segmental motion abnormalities according to
the transmural extent of the fibrotic scar.
The evaluation of the diagnostic performance of perfusion
SPECT and perfusion PET in cardiac sarcoidosis is very scarce and
limited.54–56 The potential additional value of myocardial blood
flow quantification by PET in the diagnosis and evaluation of car-
diac sarcoidosis remains to be investigated. Due to the limited
sensitivity and specificity of MPI alone, and due to the fact that
abnormal MPI alone cannot distinguish scar from active sarcoido-
sis, MPI is currently used for the evaluation of cardiac sarcoidosis
only in conjunction with FDG-PET.
When combined with FDG-PET, standard PET or SPECT MPI pro-
tocols are recommended.63–66 PET MPI has advantages over SPECT
for the identification of small perfusion defects, as seen in patients
with cardiac sarcoidosis. When SPECT imaging is used, attenuation
correction and gated imaging are recommended to avoid interpreting
segments with attenuation artifacts as segments of true mismatch.67
Perfusion and FDG abnormalities associated with cardiac sarcoidosis
are not specific for inflammation or scar from sarcoidosis.
Consequently, it is mandatory to rule out alternative diagnoses such
as CAD before interpreting myocardial perfusion images.
Combined assessment of perfusion and inflammation
The combined assessment of perfusion and inflammation, preferably
in hybrid imaging setting, is likely to provide additional information
about the status of cardiac sarcoidosis (scar or inflammation) and risk
from cardiac involvement (Figure 2). In this section we will only con-
sider the assessment of inflammation by FDG-PET/CT combined
with MPI since 67Gallium-citrate scintigraphy is no longer regarded as
a method of choice.
Perfusion defects in patients with cardiac sarcoidosis can represent
areas of scar or inflammation, while abnormal FDG uptake repre-
sents inflammation (Table 3). FDG and MPI patterns have been
described as ‘early’ (only FDG-positive), ‘progressive inflammatory’
(FDG-positive without major perfusion defects), ‘peak active’ (high
SUV FDG uptake with small perfusion defects), ‘progressive myocar-
dial impairment (high SUV FDG uptake with large perfusion defects)
or ‘fibrosis-predominant’ (FDG negative, but with perfusion
defects)55 (Figure 2B). Another staging system utilizes a nomenclature
analogous to the Scadding system for staging pulmonary sarcoidosis,
specifically, Stage 0 (normal FDG, normal perfusion), Stage 1 (FDG-
positive, normal perfusion), Stage 2 (FDG positive with perfusion
defects in the same myocardial segments), Stage 3 (FDG positive
with perfusion defects in different segments), or Stage 4 (normal
FDG, but perfusion defects).68
Notably, the pattern of perfusion and inflammation abnormal-
ities in relation to the disease status is not validated histologically
or by outcomes. However, this relationship may be important
both for diagnosis, and for the determination of prognosis and
establishing treatment,44,45,55 see next sections. It is noteworthy
that both resting perfusion defects as well as increased FDG
uptake may be caused by inflammation as well as associated
microvascular compression and local ischemia; for this reason
some perfusion defects may actually improve following immuno-
suppressive therapy.
Diagnostic accuracy
FDG-PET is an accurate tool for the detection of cardiac involve-
ment in sarcoidosis. Several studies reported on the sensitivity
and specificity of FDG-PET to detect cardiac sarcoidosis.1 These
studies have included patients with and without endomyocardial
biopsy proven cardiac involvement. However, as with the data
from the other imaging methods, most of these studies were
observational in nature, included small sample size, lacked an
adequate reference standard, were limited by referral bias, and
used different protocols.
The sensitivity of FDG-PET for detecting cardiac sarcoid is 85–
100% for most studies while the specificity is more variable (39–
100%) using the JMHW criteria as the gold standard (Table 1).53–
55,57,69,70 A recent meta-analysis of 7 studies demonstrated an
overall sensitivity of 89% and a specificity of 78% for FDG-PET.70
However, these estimates are biased as the lower specificity of
PET in some studies may reflect the fact that this test is more sen-
sitive for identifying cardiac sarcoidosis than the JMHW criteria.
Indeed, the requirement of histologically proven extra-cardiac
sarcoidosis by the JMHW criteria limits identification of isolated
cardiac sarcoidosis, whereby the disease is confined only to the
heart,71 particularly if endomyocardial biopsy is negative.
Likewise, the lower sensitivity of FDG-PET in some studies may
reflect the reduced specificity of the JMHW criteria. Several stud-
ies have compared FDG-PET, either alone or combined with PET
MPI, to 67Gallium imaging and have demonstrated improved accu-
racy for detecting cardiac sarcoid.42,53,54,57,72 Despite the high
diagnostic accuracy of FDG-PET, it is currently not included in the
most recent updated (2006) diagnostic criteria of the JMHW,

























..published by the Japan Society of Sarcoidosis and Other
Granulomatous Disorders.9 The more recent Heart Rhythm
Society Consensus Recommendations10 suggest that clinical diag-
nosis of cardiac sarcoidosis is probable if there is histological proof
of extra-cardiac sarcoidosis and one or more findings which
include a pattern consistent with cardiac sarcoidosis on imaging
(including dedicated cardiac PET, late gadolinium enhancement
(LGE) on CMR, positive 67Gallium imaging), unexplained reduced
left ventricular ejection fraction (LVEF) <40%, unexplained sus-
tained (spontaneous or induced ventricular tachycardia, VT), sec-
ond degree atrio-ventricular (AV) heart block (Type 2, also called
Mobitz Type II) or third degree heart block, steroid/immunosup-
pression responsive cardiomyopathy or heart block, and other
causes for the cardiac manifestation(s) have been reasonably
excluded.
In summary, FDG-PET is the best clinically available tool for
imaging myocardial inflammation. Careful preparation to suppress
physiological myocardial glucose utilization is essential for FDG-
PET imaging of cardiac sarcoidosis. Combined assessment of
perfusion and inflammation is necessary to provide optimal infor-
mation for the diagnosis, risk assessment, and management of car-
diac sarcoidosis.
Figure 2 (A) Example of FDG and myocardial perfusion PET in sarcoidosis. The whole body hybrid FDG PET/CT study (A) showed multiple foci
of inflammation in the mediastinum, but no active inflammation in the myocardium; hybrid imaging confirms regions of FDG uptake in the mediastinal
lymphnodes and not the myocardium. Assessment of systemic disease activity is an advantage of FDG PET compared with echocardiography or
CMR. (B) Patterns of myocardial perfusion imaging (MPI) and FDG imaging of myocardial inflammation. This figure shows rest MPI in the top row and
FDG imaging of myocardial inflammation in the bottom row. A pattern of no myocardial FDG uptake is normal if MPI is normal (A), or fibrosis when
MPI is abnormal (F, the pattern of FDG uptake represents blood pool activity). A pattern of diffuse myocardial FDG uptake represents a non-specific
finding that may be seen with incomplete suppression of physiological myocardial glucose utilization and is not diagnostic for cardiac sarcoidosis (B).
A pattern of focal myocardial FDG uptake is consistent with active myocardial inflammation without (C, D, no perfusion defect) or with coexistent fib-
rosis (E, perfusion defect). Of note, Pattern C, isolated focal FDG uptake in the basal lateral wall in the absence of a perfusion defect, abnormal wall
motion, or delayed enhancement on CMR may have reduced specificity for active myocardial inflammation.


































































CMR can provide a wide range of potentially unique information
in inflammatory and infiltrative heart disease. Specific CMR imag-
ing sequences with characteristic findings in cardiac sarcoidosis
have been reported. Although evidence from large-scale prospec-
tive clinical studies for the use of CMR in cardiac sarcoidosis is
lacking, several smaller studies have demonstrated its potential to
detect cardiac involvement in sarcoidosis and predict adverse clin-
ical outcome.
Image acquisition
Patient preparation for CMR is detailed in Supplementary data
online, Supplement 3. Standardized acquisition protocols are avail-
able for all modern cardiac enabled MRI scanners73 and in sus-
pected cardiac sarcoidosis typically include low resolution
localizer images, cine imaging in multiple planes, oedema sensitive
(T2-weighted) and late gadolinium enhancement (LGE) imaging,
with parametric mapping as an emerging addition. Images should
be acquired with standardized methods73 and in standardized and
reproducible imaging planes, allowing reliable correlation
between different components of the study. T2 weighted images,
most commonly using Short Tau Inversion Recovery (T2-STIR)
methods, are sensitive to the free water content of tissue and can
thus detect myocardial inflammation and oedema in cardiac
sarcoidosis74 (Table 4). T2-STIR methods suffer from relatively
low sensitivity however due to low contrast to noise ratio and can
also be affected by artefacts from slow moving blood at the endo-
cardial surface. LGE imaging uses dual inversion saturation recov-
ery pulse sequences to delineate myocardial tissue with expanded
extracellular space as occurs in infiltration, scaring or fibrosis.
Granulomatous infiltration in cardiac sarcoidosis can be sensitively
detected with this method as focal hyperenhancement.7,76–81
Cine CMR is most commonly performed with Steady State Free
Precession (SSFP) methods, acquiring a stack of images covering
the entire heart in the left ventricular short-axis and additional
long-axis sections. Cine CMR is the most accurate imaging method
for the measurement of left and right heart dimensions and con-
tractile function. In later stages of cardiac sarcoidosis contractile
function can be impaired and is sensitively detected and followed
up with CMR. Cine CMR also allows detection of ventricular
aneurysms, pericardial effusion and valve pathology. Increasingly,
parametric T1 and T2 mapping provide quantitative measures of
tissue inflammation, oedema and diffuse fibrosis, but are only
beginning to be used in sarcoidosis, so that, experience with these
newer methods is limited.
Interpretation and reporting
The most commonly found CMR abnormality in patients with sarcoi-
dosis is focal hyperenhancement on LGE images, usually readily
detectable by visual inspection. Mid-wall or sub-epicardial enhance-
ment in the basal ventricular wall, the lateral wall and septum is con-
sidered the most common pattern in cardiac sarcoidosis, but
subendocardial or transmural enhancement in other myocardial loca-
tions has also been described82 (Figure 3). Importantly, LGE findings
are not specific to sarcoidosis and the differential diagnosis from
myocarditis and other inflammatory conditions can be challenging.
Using thresholding methods, the extent of hyperenhancement on
LGE can be quantified to give a measure of disease extent, but no
consensus exists so far for to the optimal threshold for diagnosis.
Oedema sensitive images may show areas of high signal in patients
with cardiac sarcoidosis, suggestive of inflammation and oedema.
However, reliable detection of oedema can be difficult as T2
weighted images have a relatively low signal to noise ratio and can be
prone to artifacts, in particular from slow flow at the endocardial
boundary. A careful review of the images is therefore mandatory. By
calculating the ratio of signal in skeletal muscle and the myocardium,
....................................................................................................................................................................................................................
Table 3 Interpretation of combined rest perfusion and FDG imaging
Rest perfusion FDG Interpretation
Normal perfusion and metabolism
Normal No uptake Negative for cardiac sarcoidosis
Normal Diffuse Diffuse (usually homogeneous) FDG most likely due to suboptimal patient
preparation
Normal Isolated lateral wall uptake May be a normal variant
Abnormal perfusion or metabolism
Normal Focal Could represent early disease
Defect No uptake Perfusion defect represents scar from sarcoidosis or other etiology
Abnormal perfusion and metabolism
Defect Focal in area of perfusion defect Active inflammation with scar in the same location
Defect Focal on diffuse with focal in area
of perfusion defect
Active inflammation with scar in the same location with either diffuse inflamma-
tion or suboptimal preparation
Defect Focal in area of normal perfusion Presence of both scar and inflammation in different segments of the myocardium
Adapted from Blankstein et al.45




















a semi-quantitative measure of oedema can be derived. In sarcoidosis,
cine CMR provides quantitative measurements of volumes and EF
and shows similar abnormalities as seen on 2D echocardiography. A
CMR report in suspected sarcoidosis should include a description of
extracardiac findings (including lung nodules, splenic or hepatic perfu-
sion defects), measurements of right and left ventricular size, vol-
umes, and function, comments on pericardial and valve pathology,
presence of oedema and a description of the location and size of
lesions seen on LGE.
Diagnostic accuracy
Multi-parametric CMR is a sensitive tool for the detection of cardiac
involvement in sarcoidosis. However, to date CMR has only been
used in relatively small observational studies and as for other imaging
....................................................................................................................................................................................................................
Table 4 Recommended CMR protocol and analysis in sarcoidosis
Pulse sequence Imaging planes Analysis and tips
Morphology and
function
1. Steady State Free Precession (SSFP) cine
imaging
i. Whole heart coverage in LV
short-axis plane from the
mitral valve to the apex.
Use real time acquisition in patients
with poor breath holding.
- Slice thickness 6–8 mm, with 2–4 mm inter-
slice gaps to equal 10 mm.
ii. 4 chamber plane Report regional and global LV and RV
function as well as aneurysms and
other morphological abnormalities.- Temporal resolution <_45 ms between
phases
iii. Vertical long-axis plane
- Parallel imaging as available iv. LV outflow tract (LVOT)
plane
T2-weighted imaging 1. Black blood T2-W STIR (Short Tau
Inversion Recovery)
Same planes as for cine imaging
(short- and long-axis views)
Report presence of focal signal enhance-
ment suggestive of oedema.
2. Bright blood T2-W sequences Beware slow flow artefacts at endocar-
dial border in particular in long-axis
planes.
a. T2-prepared single-shot SSFP sequence
b. Turbo spin echo-steady SSFP hybrid
Late Gadolinium
Enhancement
1. 2D/3D segmented inversion recovery gra-
dient or SSFP pulse sequence
Same planes as for cine imaging
(short- and long-axis views)
PSIR is less dependent on correct TI.
2. Phase-Sensitive Inversion-Recovery (PSIR)
pulse sequence
Use Single Shot for patients with irregu-
lar heart rhythm, and/or difficulty
breath holding.3. Single-shot imaging (SSFP readout)
- Slice thickness same as for cine imaging Report presence of focal
hyperenhancement.
- In-plane resolution, 1.4–1.8 mm
- Inversion time to null normal myocardium. Consider using thresholding methods.
- Acquisition duration per R-R interval
below 200 ms, less in the setting of
tachycardia.
- Read-out usually every other heart beat
unless tachycardia or bradycardia
- Images acquired during diastolic stand-still.
- Acquired at least 10 min after gadolinium
injection
T2 mapping (optional) 1. T2-prepared single-shot SSFP sequence
acquired with different T2 prep time
Typically LV short-axis Acquire prior to contrast
administration.
Review maps for presence of focal signal
enhancement suggestive of oedema.
T1 mapping (optional) 1. Look Locker imaging (MOLLI or ShMOLLI
or equivalent)
Typically LV short-axis Performed prior to contrast and at 2–4
time points post-contrast bolus.
2. Saturation Recovery Single-Shot
Acquisition (SASHA)
Alternatively, constant infusion of con-
trast can be used rather than bolus.
Review maps for presence of focal signal
enhancement suggestive of oedema/
fibrosis.
Modified from Kramer et al.75
































































































modalities, prospectively designed diagnostic accuracy studies against
histological endpoints are lacking. Similar to FDG-PET studies, esti-
mates of the diagnostic accuracy of CMR in cardiac sarcoidosis are
hampered by the lack of a gold standard.
The first report on the diagnostic accuracy of CMR for cardiac sar-
coidosis showed a sensitivity of 100% and specificity of 78% vs. the
JMHW criteria.80 The relatively low specificity can be explained as
the CMR data were compared using the low diagnostic sensitive
JMHW criteria. Patel et al., showed that CMR compared with the
JMHW criteria resulted in a higher incidence of cardiac involvement
in sarcoidosis (i.e. >2-fold increase in cardiac sarcoidosis diagnosis vs.
JMHW criteria), leading to a significant improvement in prognostica-
tion of adverse events by CMR when compared with JMHW
criteria.82
The most consistently reported finding on CMR is focal LGE,
described in numerous smaller reports7,77–81 and two larger studies,
which found LGE in 39 of 155 (25.5%) and 41 of 205 (20%) patients
with extra-cardiac sarcoidosis,76,83 and a systematic review and meta-
analysis.84 Importantly, LGE was seen in patients who did not meet
standard JMHW guidelines, suggesting that CMR is a more sensitive
test to detect cardiac involvement in sarcoidosis than established diag-
nostic criteria, however specificity may be variable. Although small
reports have suggested that some lesions on LGE regress following
steroid therapy,85 this needs to be further evaluated.
Oedema sensitive T2 weighted imaging and T2 mapping have only
been used in cases series and small feasibility studies. In 32 patients
with sarcoidosis, increased signal in the interventricular septum on
T2-weighted images was more common in patients with complete
heart block than patients with normal conduction.74 T2 mapping has
been used in a study of 28 patients and showed reduced T2 values in
regions of LGE, which the authors speculate may reflect an inactive
phase of the disease.86
The above limitations related to evaluating the diagnostic accuracy
of CMR, similar to the ones for FDG-PET underscore the importance
of evaluating the prognostic findings provided by various imaging
results, as the ultimate identification of patients who have a higher risk
of adverse events may be most important for guiding therapy. Finally,
as discussed in ‘Approach to sarcoidosis imaging procedures’ section,
with the exception of a few small reports, focal LGE by CMR has con-
sistently been linked with adverse clinical outcome.76,77,87,88
Of equal importance, the absence of LGE in patients with sus-
pected cardiac sarcoidosis is generally associated with a favour-
able prognosis,76 although some studies have shown conflicting
findings.77
In summary, CMR is a multi-parametric imaging modality that can
accurately delineate cardiac morphology and function and interrog-
ate tissue characteristics. CMR is a valuable tool for the diagnosis and
risk assessment of cardiac sarcoidosis. Whether CMR can be used to
assess response to therapy is unclear, as CMR findings are limited by
a relatively low specificity to distinguish scar from active inflammation.
However, the relatively high sensitivity of the technique contributes
to the exclusion of cardiac sarcoidosis.
Computed tomography
CT plays a limited role in the evaluation and management of patients
with systemic sarcoidosis. Although, cardiac CT has no established
role for the diagnosis of cardiac sarcoidosis, coronary CT angiogra-
phy may play an important role in excluding CAD in individuals with
LV dysfunction and regional wall motion abnormalities.
Imaging to guide biopsy
Cardiac involvement is often difficult to diagnose because endomyo-
cardial biopsy is limited by sampling error and complication risk cannot
be ignored.45,89,90 The diagnosis of isolated cardiac involvement is
therefore difficult and laboratory abnormalities are non-specific. If the
likelihood of an inflammatory cardiomyopathy remains high despite a
negative endomyocardial biopsy, pursuing the diagnosis with repeated
and image-guided biopsies of the myocardium or mediastinal lymph
nodes is worthwhile and may markedly improve the detection rate of
cardiac sarcoidosis.91 Biopsy guided by electromechanical mapping has
also been used for the diagnosis of isolated cardiac sarcoidosis.92
Although focal myocardial LGE, high T2 signal on CMR, and increased
glucose uptake on cardiac FDG-PET are non-specific signs of myocar-
dial damage or inflammation, in patients with histologically proven
extra-cardiac sarcoidosis they provide sensitive signs of sarcoid involve-
ment of the heart.54,82 In patients with biopsy-proven cardiac sarcoido-
sis, abnormal LGE and FDG-PET findings were observed in 94% and
80% of patients, respectively.91 However, without histopathological
verification, even typical abnormalities on CMR or PET may not pro-
vide a definitive diagnosis and decisions regarding long-term
Figure 3 Example of cardiac sarcoidosis diagnosed with CMR.
Late gadolinium enhanced CMR image from an Afro-Caribbean male
who presented with pulmonary sarcoidosis and suspected cardiac
involvement. The image shows focal mid-myocardial contrast
enhancement in the basal inferior and lateral wall and septum. (Image
courtesy Dr Tevfik Ismail, King’s College London, United Kingdom.)






































..immunosuppression in such patients with suspected, but not proven,
cardiac sarcoidosis remains challenging and must be individualized. The
role of hybrid PET/CT and PET/MRI to guide biopsy remains to be eval-
uated (see ‘Future directions’ section).
In summary, abnormal cardiac findings on CMR and/or FDG-PET
are frequent and suggest localized areas of myocardial damage and/or
inflammation in patients with cardiac sarcoidosis. In a clinical setting
suggestive of cardiac sarcoidosis, ‘hot’ mediastinal or cervical lymph
nodes on FDG-PET provide a biopsy target that may improve the suc-
cess rate of identifying sarcoid histopathology. The potential role of
image-guided endomyocardial biopsy to improve the yield for histopa-
thological diagnosis of cardiac sarcoidosis requires further evaluation.
Imaging to initiate and monitor
therapy
Immunosuppressive therapy is frequently used to treat cardiac sar-
coidosis. Sarcoidosis experts, using a Delphi study method, agreed on
the treatment of cardiac sarcoidosis with immunosuppressive
therapy for the following clinical scenarios: LV dysfunction, ventricu-
lar arrhythmias, hypermetabolic activity on cardiac FDG-PET, pres-
ence of conduction defects, LGE on CMR, or right ventricular
dysfunction in the absence of pulmonary hypertension.93 But, due to
high side effect profile of immunosuppressive drugs, image guided ini-
tiation and tailoring of therapy are critical.
A multimodality imaging approach may be necessary for the deci-
sion making about pacemaker or ICD.10 Per HRS guidelines,10 ICD is
indicated, if LVEF remains <35% after immunosuppressive therapy
(Class I) or if LGE is present in patients with LVEF 35–49% after
immunosuppression (Class IIb).
Echocardiography and/or CMR features are not very specific for
inflammation. However, they may help in the assessment of LV
remodeling, left as well as right ventricular function, pulmonary artery
hypertension and in the follow-up of end stage heart failure from car-
diac sarcoidosis before and after heart transplantation.25 The use of
echocardiography and CMR (and LGE) to assess changes in inflamma-
tion in response to therapy is limited.94
Observational studies suggest an important role for FDG-PET
to monitor efficacy of immunosuppressive therapy.53 Osborne
Figure 4 Example of FDG and myocardial perfusion PET in sarcoidosis: Assessing response to therapy with FDG PET. A 48 year old man with mild
exertional dyspnea with exercise that progressed to more severe dyspnea and with lightheadedness and dizziness. His ECG should complete heart
block with ventricular escape rate of 45 bpm, catheterization revealed no coronary artery disease, and his left ventricular ejection fraction was 52%.
A cardiac MRI suggested four areas of inflammatory/infiltrative processes in the basal septal and anteroseptal regions. A CT scan of the chest revealed
enlarged mediastinal lymph nodes and bilateral pulmonary nodules. An endomyocardial biopsy showed non-specific mild hypertrophy. A mediastino-
scopy with biopsy of a mediastinal lymph nodes confirmed extensive (confluent) non-necrotizing granulomas consistent with sarcoidosis. An FDG
PET scan was performed prior to initiation of Prednisone therapy. It revealed multiple foci of inflammation in the left and right ventricular walls (SUV
max 5.7) as well as in the mediastinum. Oral prednisone 40 mg per day was initiated and an ICD was implanted. Three months after high dose steroid
therapy, a repeat FDG PET scan showed that myocardial (SUV max 1.5) and mediastinal inflammation is substantially decreased (blood pool FDG
activity is noted), but splenic and abdominal lymph node inflammation persisted. No myocardial perfusion defects were noted suggesting no regions
of fibrosis.






































..et al. examined 23 patients who underwent serial FDG-PET exams
during treatment for cardiac sarcoidosis. They showed that a quan-
titative reduction in the intensity (i.e. SUV max) or extent (i.e. vol-
ume of inflammation above a pre-specified SUV threshold) was
associated with improvement in LVEF.59 Although clear response
to therapy is seen in some case, (Figure 4) the use of visual analysis
to assess serial changes in response to therapy may be limited par-
ticularly when there is partial response (see ‘Myocardial perfusion
imaging’ section). Quantitative metrics of SUVmax as well as vol-
ume of myocardial pixels with SUV above a certain threshold, and
changes in extent and severity of myocardial perfusion, may be
preferred to assess response to therapy. Whether steroid induced
glucose metabolic changes influence FDG uptake by the myocar-
dium is not known. The duration of treatment is based on clinical
response and can be guided by disease activity on FDG PET, Figure
6.88 The optimal timing to repeat FDG-PET imaging is not known.
We suggest repeating FDG PET approximately 4–6 months after
initiation of therapy.
In summary, in the absence of specific guidelines, in asymptomatic
patients with cardiac sarcoidosis, echocardiography is useful to
follow-up LVEF and to evaluate for new wall motion abnormalities,
wall thinning. A quantitative FDG-PET with MPI may be useful to
monitor progression of scar and inflammation and assess response to
active immunosuppressive therapies. Prospective randomized clinical
trials of imaging guided management of immunosuppressive therapy
are warranted.
Prognosis
Several groups of investigators have studied the value of structural
and functional myocardial changes of cardiac sarcoidosis detected
on echocardiography, CMR and FDG-PET in predicting prognosis
(Table 5). The extent of LV dysfunction and dilatation at baseline are
important predictors of survival.23 Further, a reduced global longitu-
dinal strain is an independent predictor of adverse events among
patients with suspected cardiac sarcoidosis.25 The presence of LGE
on CMR, including focal LGE,76 and the extent of LGE (LGE
mass >_ 20% of LV mass), is associated with a higher risk of death or
VT and a lower likelihood of improvement in LV function.83,99 The
....................................................................................................................................................................................................................
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prognostic value of other CMR findings have been less well studied
and no reports are available for T2 weighted CMR. In one study,
LVEF was a weaker prognosticator than LGE.83 Importantly, patients
who do not have any late enhancement had an extremely low event
rate, with very few cardiac events reported. Therefore, CMR may be
used not only to exclude the presence of cardiac sarcoidosis in the
vast majority of patients with suspected disease, but also to identify
patients who have an excellent prognosis, with a strong value of LGE.
Also, patients with a combination of (a) increased myocardial inflam-
mation (i.e. focal uptake of FDG) and (b) resting perfusion defects are
at high risk for death or VT (four-fold increased risk),45 independent
of LVEF, clinical criteria, and the presence of active extra-cardiac dis-
ease.44,45 In addition, the presence of focal uptake of FDG by the right
ventricle was found to be associated with an extremely high event
rate. Notably, the presence or absence of active extra-cardiac sarcoi-
dosis was not associated with adverse events.
Based on the published studies to date, the event rate in
patients referred for cardiac PET is higher than those referred for
CMR. This difference can be explained by the fact that patients
referred for PET are more likely to already have an ICD (which is
sometimes a contraindication for CMR) and prior history of VT.
Therefore, this most likely reflects a referral bias based on the fact
that patients referred for PET imaging have higher degree of dis-
ease activity.97,98
In summary, while there is a paucity of data in this regard, it
seems plausible that the findings provided by echocardiography
(which provides an estimate of myocardial remodeling and func-
tion), CMR (which provides an estimate of the extent of scar), PET
imaging with FDG (which provide an estimate of the overall magni-
tude and extent of myocardial inflammation), and MPI (which
provides an estimate of microvascular dysfunction and/or scar)
may be complementary, both for diagnosing and treating disease,
as well as for providing an estimate of the risk of future adverse
events.
Approach to sarcoidosis imaging
procedures
The approach to cardiac sarcoidosis imaging may include multiple
imaging tests (Figure 5). The main indications for advanced imaging in
cardiac sarcoidosis: (i) suspected cardiac involvement in patients with
biopsy-proven extracardiac sarcoidosis and symptoms (unexplained
syncope/presyncope/significant palpitations), and/or abnormal ECG
and/or inconclusive echocardiogram10; (ii) suspected relapse in a
patient with a history of cardiac sarcoidosis; (iii) treatment monitor-
ing in patients diagnosed with cardiac sarcoidosis. In addition,
advanced imaging may contribute to (iv) prognostic assessment that
may impact on therapeutic management and follow up.19,99,100
Radionuclide imaging, particularly FDG-PET with SUV quantitation
and in conjunction with myocardial perfusion imaging, may be useful
to not only detect myocardial inflammation but also to monitor pro-
gression of scar and inflammation and assess response to active
immunosuppressive therapies (Figure 6).
Future directions
The future of cardiac sarcoidosis imaging relies on development of
novel inflammation specific radiotracers, hybrid imaging devices,
Figure 5 Non-invasive imaging approach to initial evaluation of patients with suspected cardiac sarcoidosis. CS, cardiac sarcoidosis; CMR, cardio-
vascular magnetic resonance imaging; ECG, electrocardiogram; Echo, echocardiogram; FDG, 18F-fluorodeoxyglucose; ICD, implantable cardioverter
defibrillator; LGE, late gadolinium enhancement; MPI, myocardial perfusion imaging; Rx, therapy. †Identify coexistent inflammation; FDG PET/CT may
be preferred first test in individuals with known systemic sarcoidosis where systemic sarcoidosis activity needs to be assessed. *If clinical suspicion is
high or symptoms persist, FDG PET/CT and MPI may be considered in patients with normal CMR. ‡Immunosuppressive Rx may be considered taking
into account the amount of inflammation. Patients with ICD are excluded for CMR.
































































































as well as multi-disciplinary and multi-institutional collaborations
using standardized imaging methods. Novel somatostatin receptor
binding radiopharmaceuticals such as 68Ga-DOTATOC/TATE/
NOC, radiotracers of inflammation (11C-PBR28) and 18F-FLT (flu-
orothymidine) as well as novel CMR contrast agents such as
Ferumoxytol (contrast agent consisting of ultrasmall superpara-
magnetic particles of iron oxide (USPIOs) that are taken up by
macrophages, are under evaluation (clinicaltrials.gov). In addition,
novel hybrid imaging systems combining PET and MRI (PET/MRI
camera) provide highly complementary information on tissue
characterization and metabolic information in one single
session.101,102 Due to the lack of a gold standard for the diagnosis
of cardiac sarcoidosis, the lack of specificity of the imaging findings,
and the potential risk of high-dose immunosuppressive therapies,
sarcoidosis is challenging to diagnose and manage. A multidiscipli-
nary heart team approach involving experienced imagers (echo-
cardiography, CMR, and radionuclide imaging), internal medicine
physicians, cardiologists, heart failure physicians, pulmonary physi-
cians, electrophysiologists, rheumatologists, pathologists, and
others will be critical to manage sarcoidosis.
Conclusions
Sarcoidosis is a complex systemic disease that often requires multi-
disciplinary expertise and approach for diagnosis and management.
Detection of cardiac sarcoidosis is important to prevent life-
threatening arrhythmias and to preserve LV function in affected indi-
viduals. A multi-imaging approach that can identify disease activity,
prognosis and response to therapy is needed to improve further the
management of patients with cardiac sarcoidosis. Optimal imaging
based on standardized procedural guidelines for acquisition, interpre-
tation, and quantification is paramount.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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